EUCTR2017-001168-39-PL进行中（未招募）1 期
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo- Controlled, Multi-Center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents. - SNR-01-NaBen
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 126
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects are required to meet all of the following criteria for randomization into the study.
- •1. Male or female subjects who are between 12 and 17 years of age inclusive
- •2. Physician confirmed DSM-IV or -V diagnosis of schizophrenia based on the MINI International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders Studies for Children and Adolescents, version 6.0 (MINI-KID, Version 6.0) (Sheehan, 2010) (refer to Appendix 19.1)
- •3. Are clinically stable with residual symptoms. Residual symptoms will be defined as a total score of = 60 of PANSS and a score of = 40 for SANS
- •4. An unchanged antipsychotic medication regimen for at least eight (8) weeks prior to randomization into the study and expected to remain unchanged during the study (longer for depot or long-acting antipsychotics: ten (10) months for
- •Aripiprazole (Maintena®) and Paliperidone (Xeplion®); six (6) months for Olanzapine pamoate monohydrate (Zypadhera®); and at least 6 times duration of the reported half life or minimum four (4) months for other depot or long-acting antipsychotics)
- •5. In good general physical health and all physical exam, neurological exam and laboratory assessments (urine/blood routine, biochemical tests and electrocardiogram [ECG]) are clinically unremarkable per the Investigator
- •6. Subject has a negative urine illicit drug screening test
- •7. Subject understands and is willing to sign the IAF prior to study entry and agrees to be available for all the study visits
- •8. The subject’s guardian understands and is willing to sign the ICF prior to study entry and agrees to be available for all the study visits
- •9. Must not be a danger to self or others and must have family support available to be maintained as outpatients
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 126
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria will be excluded from randomization into the study:
- •1. Meets the DSM-IV or -V criteria at screening for mental retardation, dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, or primary substance-induced psychotic disorder. Other comorbid disorders; e.g., attention-deficit hyperactivity disorder (ADHD), are allowed as long as schizophrenia is the primary diagnosis and the comorbid disorder(s) do not require medication.
- •2. Subjects whose illness was resistant to antipsychotics according to prior trials of two different antipsychotics of adequate dose
- •3. History of epilepsy, head trauma, or neurological illness other than Tourette’s syndrome
- •4. History of allergic reaction to sodium benzoate
- •5. Serious medical illnesses such as acute or chronic renal disease, liver failure or heart disease that, in the opinion of the Investigator, may interfere with the conduct of the study.
- •6. Current substance abuse or positive urine illicit drug screening or history of substance dependence (including alcohol, but excluding nicotine and caffeine) in the past three (3) months.
- •7. Inability to follow protocol
- •8. Body Mass Index (BMI) > 35
- •9. Female subjects who are pregnant (as confirmed by urine pregnancy test performed at screening Visit) or are nursing, or who do not agree to abstinence or birth control during the study
- •10. Cancer within the last three (3) years except for basal cell carcinoma and squamous cell carcinoma
- •11. Previous participation in an intervention trial within 30 days of randomization
- •12. Decrease in the PANSS total score by more than 10 percent using PANSS evaluations performed at Screening Visit 1 and Screening Visit 3
研究者
相似试验
进行中（未招募）
1 期
Two-part Clinical Study to Evaluate the Safety and Benefits of NaBen® in Adolescents with SchizophreniaTreatment for Schizophrenia in AdolescentsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-001168-39-GBSyneuRx International (Taiwan) Corp126
进行中（未招募）
1 期
Two-part Clinical Study to Evaluate the Safety and Efficacy of NaBen® in Adults with Refractory SchizophreniaTreatment for Refractory Schizophrenia in AdultsEUCTR2017-001170-42-DESyneuRx International (Taiwan) Corp287
进行中（未招募）
1 期
Two-part Clinical Study to Evaluate the Safety and Efficacy of NaBen® in Adults with Refractory SchizophreniaTreatment for Refractory Schizophrenia in AdultsEUCTR2017-001170-42-GBSyneuRx International (Taiwan) Corp287
进行中（未招募）
1 期
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecurrent/Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2019-003981-42-DKGlaxoSmithKline Research & Development Ltd640
进行中（未招募）
1 期
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecurrent/Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2019-003981-42-GRGlaxoSmithKline Research & Development Ltd116